ALLERGAN
Allergan, Inc.
The mark consists of the word "ALLERGAN" in a stylized dark blue font to the left of which is a stylized futuristic comet design comprised of circles that are as follows moving from right to left: three large dark blue circles, followed next by four medium blue circles that are large on the outside with the two middle circles being smaller, followed next by three small light blue circles, followed next by three large green circles, followed next by three smaller medium green circles, followed next by three small yellow circles, with the last circle being the point of the comet.
Mark For: ALLERGAN® trademark registration is intended to cover the categories of
>The color(s) dark blue, medium blue, light blue, green, medium green, and yellow is/are claimed as a feature of the mark. The mark consists of the word "ALLERGAN" in a stylized dark blue font to the left of which is a stylized futuristic comet design comprised of circles that are as follows moving from right to left: three large dark blue circles, followed next by four medium blue circles that are large on the outside with the two middle circles being smaller, followed next by three small light blue circles, followed next by three large green circles, followed next by three smaller medium green circles, followed next by three small yellow circles, with the last circle being the point of the comet.
| Research |
OneLook
Acronym Finder
|
| Serial Number | 86983196 |
| Registration Number | 5443889 |
| Mark Literal Elements | ALLERGAN |
| Mark Drawing Type | 3 - AN ILLUSTRATION DRAWING WHICH INCLUDES WORD(S)/ LETTER(S)/NUMBER(S) |
| Mark Type | TRADEMARK |
| Standard Character Claim | No |
| Register | PRINCIPAL |
| Current Location | PUBLICATION AND ISSUE SECTION 2018-03-02 |
| Basis | 1(a) |
| Class Status | ACTIVE |
| Primary US Classes |
|
| Primary International Class |
|
| Filed Use | No |
| Current Use | Yes |
| Intent To Use | No |
| Filed ITU | Yes |
| 44D Filed | No |
| 44E Current | No |
| 66A Current | No |
| Current Basis | No |
| No Basis | No |
| Law Office Assigned | L90 |
| Employee Name | MARESCA, MEREDITH Z |
Timeline
| 2015-06-12 | Application Filed |
| 2016-03-01 | Published |
| 2016-03-01 | Published for Opposition |
| 2017-06-30 | Date of First Use |
| 2017-06-30 | Date of Use In Commerce |
| 2018-03-02 | Location: PUBLICATION AND ISSUE SECTION |
| 2018-04-10 | Status: Live/Registered |
| 2018-04-10 | Status: Registered. The registration date is used to determine when post-registration maintenance documents are due. |
| 2018-04-10 | Trademark Registered |
| 2018-07-08 | Transaction Date |
| 2023-04-10 | Maintenance Early File Date |
| 2024-04-10 | Maintenance On Time Date |
| 2024-10-10 | Maintenance Late Fee Date |
Trademark Parties (Applicants & Owners)
| Party: |  Allergan, Inc. |
| Address | 2525 Dupont Drive Irvine, CALIFORNIA UNITED STATES 92612 |
| Legal Entity Type | Corporation |
| Legal Entity State | DELAWARE |
Documents
Application
DrawingDesign Search Codes
| 26.01.21 | Circles that are totally or partially shaded. |
| 26.01.31 | Circles |
| 29.03.03 | Blue (single color used on a portion of the goods) |
| 29.03.06 | Green (single color used on a portion of the goods) |
| 29.06.03 | Blue (multiple colors used on a portion of the goods) |
| 29.06.06 | Green (Multiple colors used on a portion of the goods) |
| 010107 | Comets; Stars with tails or comets |
| 260121 | Circles that are totally or partially shaded. |
| 260131 | Circles |
| 290303 | Blue (single color used on a portion of the goods) |
| 290306 | Green (single color used on a portion of the goods) |
| 290603 | Blue (multiple colors used on a portion of the goods) |
| 290606 | Green (Multiple colors used on a portion of the goods) |
Attorney of Record
Good, Services, and Codes
IC 005. US 006 018 044 046 051 052. G & S: House mark used for a line of pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations, and pharmaceutical preparations to treat and prevent glaucoma; ocular wetting solutions, namely, eye drops, artificial tears and gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system disorders, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body; medicated cosmetic skin care preparations. FIRST USE: 20170630. FIRST USE IN COMMERCE: 20170630
IC 010. US 026 039 044. G & S: House mark used for a line of surgical, medical, dental and veterinary apparatus and instruments, namely, diagnostic test kits principally composed of medical diagnostic meters that measure conditions of the cardio-vascular and immune systems; intra-uterine non-chemical contraceptive devices; medical diagnostic instruments for the analysis of body fluids; medical devices for treating glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for use in facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics and ophthalmic related diseases and disorders. FIRST USE: 20161012. FIRST USE IN COMMERCE: 20161012
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| International Codes: | 10 |
| U.S. Codes: | 026,039,044 |
| Type Code | Type |
|---|---|
| CC0000 | The color(s) dark blue, medium blue, light blue, green, medium green, and yellow is/are claimed as a feature of the mark. |
Trademark Filing History
| Description | Date | Proceeding Number |
|---|---|---|
| REGISTERED-PRINCIPAL REGISTER | 2018-04-10 | |
| NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | 2018-03-03 | |
| ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | 2018-03-02 | |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2018-02-09 | 68552 |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2018-02-09 | 68552 |
| TEAS REQUEST FOR RECONSIDERATION RECEIVED | 2018-02-08 | |
| SU - FINAL REFUSAL - WRITTEN | 2017-10-27 | 89015 |
| NOTIFICATION OF FINAL REFUSAL EMAILED | 2017-10-27 | |
| FINAL REFUSAL E-MAILED | 2017-10-27 | |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2017-10-25 | 68552 |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2017-10-25 | 68552 |
| ASSIGNED TO LIE | 2017-10-24 | 68552 |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2017-10-10 | |
| SU - NON-FINAL ACTION - WRITTEN | 2017-10-04 | 89015 |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2017-10-04 | |
| NON-FINAL ACTION E-MAILED | 2017-10-04 | |
| NOTICE OF DESIGN SEARCH CODE E-MAILED | 2017-09-29 | |
| STATEMENT OF USE PROCESSING COMPLETE | 2017-09-28 | 71034 |
| DIVISIONAL PROCESSING COMPLETE | 2017-09-28 | |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2017-09-28 | 71034 |
| USE AMENDMENT FILED | 2017-09-20 | 71034 |
| TEAS STATEMENT OF USE RECEIVED | 2017-09-20 | |
| TEAS REQUEST TO DIVIDE RECEIVED | 2017-09-20 | |
| DIVISIONAL REQUEST RECEIVED | 2017-09-20 | |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2017-03-28 | |
| TEAS EXTENSION RECEIVED | 2017-03-24 | |
| EXTENSION 2 GRANTED | 2017-03-24 | 98765 |
| EXTENSION 2 FILED | 2017-03-24 | 98765 |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2016-09-16 | |
| TEAS EXTENSION RECEIVED | 2016-09-14 | |
| EXTENSION 1 GRANTED | 2016-09-14 | 98765 |
| EXTENSION 1 FILED | 2016-09-14 | 98765 |
| NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2016-04-26 | |
| PUBLISHED FOR OPPOSITION | 2016-03-01 | |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2016-03-01 | |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2016-02-10 | |
| NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 2016-01-22 | 6328 |
| EXAMINERS AMENDMENT E-MAILED | 2016-01-22 | 6328 |
| EXAMINERS AMENDMENT -WRITTEN | 2016-01-22 | 89015 |
| EXAMINER'S AMENDMENT ENTERED | 2016-01-22 | 88888 |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2016-01-22 | |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2016-01-20 | 88889 |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2016-01-19 | |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2016-01-19 | 88889 |
| PRIORITY ACTION WRITTEN | 2015-09-22 | 89015 |
| PRIORITY ACTION E-MAILED | 2015-09-22 | 6326 |
| NOTIFICATION OF PRIORITY ACTION E-MAILED | 2015-09-22 | 6326 |
| ASSIGNED TO EXAMINER | 2015-09-22 | 89015 |
| NOTICE OF DESIGN SEARCH CODE E-MAILED | 2015-06-18 | |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2015-06-17 | |
| NEW APPLICATION ENTERED IN TRAM | 2015-06-16 |
Similar Marks
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 